MacroGenics, Inc.
1500 East Gude Drive
Rockville
Maryland
20850-5307
United States
196 articles with MacroGenics, Inc.
-
MacroGenics to Participate in Upcoming Investor Conference
5/19/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in Cowen’s 2nd Annual Virtual Oncology Innovation Summit. MacroGenics’ management will participate in a fireside chat with the analyst on Thursday, May 20, 2021, at 9:20 am ET.
-
MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
5/19/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced preliminary safety and anti-tumor activity data from the Company’s ongoing Phase 1 clinical trial of MGC018.
-
MacroGenics Provides Update on Corporate Progress and First Quarter 2021 Financial Results
4/29/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2021.
-
MacroGenics Announces Date of First Quarter 2021 Financial Results Conference Call
4/19/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2021 after the market closes on Thursday, April 29, 2021.
-
MacroGenics Announces Presentations at the 2021 AACR Annual Meeting
4/10/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced presentations at the American Association for Cancer Research Annual Meeting, taking place April 10-15, 2021.
-
MacroGenics to Participate in Upcoming Investor Conferences - Feb 26, 2021
2/26/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in March:
-
MacroGenics Provides Update on Corporate Progress and 2020 Financial Results
2/25/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2020.
-
MacroGenics Announces Date of Fourth Quarter and Full Year 2020 Financial Results Conference Call
2/18/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year ended December 31, 2020 after the market closes on Thursday, February 25, 2021. MacroGenics will host a conference call to discuss the financial results and r
-
MacroGenics Names Federica O’Brien to its Board of Directors
2/11/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the appointment of Federica “Freddi” O’Brien, President of CFO’Brien Consulting, LLC, to its Board of Directors.
-
MacroGenics Announces Achievement of $10 Million Milestone Related to Retifanlimab Collaboration with Incyte
2/11/2021
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that a $10 million milestone has been achieved related to development progress of retifanlimab outside the U.S., under its exclusive global collaboration and license agreement with Incyte.
-
MacroGenics to Participate in Upcoming Investor Conferences - Feb 08, 2021
2/8/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in February
-
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
1/25/2021
MacroGenics today announced the publication of results from the SOPHIA trial of MARGENZA
-
MacroGenics to Participate in Upcoming Investor Conferences - Jan 11, 2021
1/11/2021
MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company's management will participate in the following investor conferences in January:
-
MacroGenics Announces MGD019 Publication in Cell Reports MedicinePD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study
12/22/2020
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript on MGD019, an investigational PD-1 × CTLA-4 bispecific DART molecule, in Cell Reports Medicine . MacroGenics’ DART platform allows for the creation of bispecific antibody-based molecules with the ability to bind t
-
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
12/18/2020
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced today a research collaboration and global license agreement to develop a preclinical bispecific molecule with Janssen Biotech, Inc.
-
The U.S. Food and Drug Administration (FDA) had several approvals this week. Read on to see what the regulatory agency gave the go-ahead to.
-
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
12/16/2020
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens
-
FDA Action Alert: MacroGenics and Amgen
12/14/2020
As the year wraps up, there are still some PDUFA dates on the agency’s calendar. Read on for this week’s. -
MacroGenics Presents Tebotelimab Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma at the 2020 ASH Annual Meeting
12/7/2020
Preliminary duration of response of up to 168 days observed, with six of seven ongoing responses as of cut-off date
-
MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting
12/6/2020
MacroGenics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced updated results from a single-arm, registrational study of flotetuzumab, an investigational, bispecific CD123 × CD3 DART® molecule, in patients with primary induction failure and early relapsed acute myeloid leukemia.